DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $324,019 | +18.2% | 1,306 | +14.4% | 0.08% | +21.9% |
| Q2 2023 | $274,080 | -22.5% | 1,142 | -18.6% | 0.06% | -20.0% |
| Q1 2023 | $353,612 | +100932.0% | 1,403 | +6.4% | 0.08% | +5.3% |
| Q4 2022 | $350 | -99.9% | 1,319 | -23.4% | 0.08% | -24.8% |
| Q3 2022 | $445,000 | -30.7% | 1,722 | -32.0% | 0.10% | -20.5% |
| Q2 2022 | $642,000 | -40.6% | 2,532 | -31.2% | 0.13% | -13.6% |
| Q1 2022 | $1,080,000 | -12.5% | 3,682 | -1.8% | 0.15% | -12.0% |
| Q4 2021 | $1,234,000 | +2.9% | 3,750 | -4.8% | 0.17% | -1.2% |
| Q3 2021 | $1,199,000 | +10.9% | 3,939 | -2.3% | 0.17% | +1.8% |
| Q2 2021 | $1,081,000 | +21.2% | 4,030 | +1.7% | 0.17% | +13.7% |
| Q1 2021 | $892,000 | -5.0% | 3,961 | -6.3% | 0.15% | -9.3% |
| Q4 2020 | $939,000 | +48.3% | 4,227 | +43.6% | 0.16% | -35.9% |
| Q3 2020 | $633,000 | +3.6% | 2,944 | -14.8% | 0.25% | +3.7% |
| Q2 2020 | $611,000 | – | 3,457 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |